Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Vir Biotechnology, Inc. (VIR : NSDQ)

• Company Description    Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. Vir Biotechnology Inc. is based in San Francisco, United States. Number of Employees: 408

• Price / Volume Information    Yesterday's Closing Price: $5.98 Daily Weekly Monthly 20 Day Moving Average: 1,507,849 shares Shares Outstanding: 138.92 (millions) Market Capitalization: $830.72 (millions) Beta: 1.27 52 Week High: $14.45 52 Week Low: $4.16 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 8.93% 6.55% 12 Week 18.89% 9.19% Year To Date -18.53% -29.44%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1800 OWENS STREET SUITE 900 - SAN FRANCISCO,CA 94158 USA ph: 415-906-4324 fax: - ir@vir.bio http://www.vir.bio

• General Corporate Information    Officers Marianne De Backer - Chief Executive Officer and Director Vicki Sato - Chairman Jason O'Byrne - Executive Vice President and Chief Financial Offic Brent Sabatini - Senior Vice President and Chief Accounting Officer Norbert Bischofberger - Director Peer Information Vir Biotechnology, Inc. (CORR.) Vir Biotechnology, Inc. (RSPI) Vir Biotechnology, Inc. (CGXP) Vir Biotechnology, Inc. (BGEN) Vir Biotechnology, Inc. (GTBP) Vir Biotechnology, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 92764N102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/05/25 Share - Related Items Shares Outstanding: 138.92 Most Recent Split Date: (:1) Beta: 1.27 Market Capitalization: $830.72 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.64 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.11 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 12.57% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.88 Price/Cash Flow: - Price / Sales: 43.72 EPS Growth vs. Year Ago Period: 21.57% vs. Previous Quarter: 9.09% Sales Growth vs. Year Ago Period: -60.52% vs. Previous Quarter: -59.96% ROE 09/30/25 - - 06/30/25 - -50.22 03/31/25 - -47.46 ROA 09/30/25 - - 06/30/25 - -40.78 03/31/25 - -39.33 Current Ratio 09/30/25 - - 06/30/25 - 7.01 03/31/25 - 6.79 Quick Ratio 09/30/25 - - 06/30/25 - 7.01 03/31/25 - 6.79 Operating Margin 09/30/25 - - 06/30/25 - -2,895.94 03/31/25 - -2,769.04 Net Margin 09/30/25 - - 06/30/25 - -2,895.94 03/31/25 - -2,769.04 Pre-Tax Margin 09/30/25 - - 06/30/25 - -2,894.48 03/31/25 - -2,775.77 Book Value 09/30/25 - - 06/30/25 - 6.82 03/31/25 - 7.56 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©